A 12 week, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of concentrated powder of Oenanthe javanica on improving liver function.

MSC0 个研究点目标入组 76 人开始时间: 待定最近更新: 2019年3月11日

试验速览

暂无简介。

•1. Between more than the normal value of normal AST, ALT, and GGT and less than 3 times of normal AST, ALT, and GGT level
•(AST;39-114, ALT;44-129, and GGT:76-225 at screening period)

•1. patients who are taking treatment due to alcohol abuse, alcohol-related disease, heart disease and CNS disease
•2. liver cirrhosis or hepatoma on sonography
•3. viral hepatitis
•4. HBs Ag(+), or HCV Ab(+)
•5. sujects who took medication of liver mediated metabolism such ad INH, valproic acid, tetracycline, allopurinol, ibuprofen, phenytoin phenelzin, sertraline, naproxen, diclofenac, and any drug affecting liver toxicity within 4 weeks before enroll.
•6. subjects who are taking steroid or sex hormone within 4 weeks before enroll.
•7. intractable hypertension(over 160/100mg) or DM with more than 180mg/dl of fasting glucose .
•8. Newly taking antilipidemic drug of DM medication wihtin 3 months before enroll.
•9. during pregnancy or plan of pregnancy
•10. subjects who are registered on the other clinical research within 1 month before enroll.
•11. subjects pressumed as not appropriate by researchers.

发起方